American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 238-247 , August 2009

Physician Characteristics and Knowledge of CKD Management

  • Rubeen K. Israni, MD, MSCE

      Affiliations

    • Renal and Hypertension Division, Department of Medicine, Christiana Care Health System, Newark, DE
    • Corresponding Author InformationAddress correspondence to Rubeen K. Israni, MD, MSCE, 4755 Ogletown-Stanton Rd, Newark, DE 19718
    • ,
  • Judy A. Shea, PhD

      Affiliations

    • Department of Medicine, University of Pennsylvania Health System, Philadelphia, PA
    • ,
  • Marshall M. Joffe, MD, PhD

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA
    • ,
  • Harold I. Feldman, MD, MSCE

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA
    • Renal, Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA

Received 1 September 2008 ,Accepted 22 January 2009.

References 

  1. Saydah S, Eberhardt M, Rio-Burrows N, Williams D, Geiss L, Dorsey R. Prevalence of chronic kidney disease and associated risk factors—United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56:161–165
  2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  4. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745–753
  5. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616
  6. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–1140
  7. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479–486
  8. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001;12:2832–2837
  9. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295
  10. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207–1216
  11. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. Am J Hypertens. 2001;14:1219–1225
  12. Israni A, Korzelius C, Townsend R, Mesler D. Management of chronic kidney disease in an academic primary care clinic. Am J Nephrol. 2003;23:47–54
  13. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med. 2006;166:1884–1891
  14. Patwardhan MB, Samsa GP, Matchar DB, Haley WE. Advanced chronic kidney disease practice patterns among nephrologists and non-nephrologists: A database analysis. Clin J Am Soc Nephrol. 2007;2:277–283
  15. Tiwari A, Tseng CL, Kern EF, Maney M, Miller DR, Pogach L. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease. Am J Manag Care. 2007;13:73–79
  16. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  17. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  18. Gorsuch RL. Factor Analysis. (ed 2). London, England: Erlbaum; 1983;
  19. Pett MA, Lackey NR, Sullivan JJ. Making Sense of Factor Analysis: The Use of Factor Analysis for Instrument Development in Health Care Research. Thousand Oaks, CA: Sage; 2003;
  20. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification and referral of patients with progressive CKD: A national study. Am J Kidney Dis. 2006;48:192–204
  21. Akbari A, Swedko PJ, Clark HD, et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program. Arch Intern Med. 2004;164:1788–1792
  22. Wyatt C, Konduri V, Eng J, Rohatgi R. Reporting of estimated GFR in the primary care clinic. Am J Kidney Dis. 2007;49:634–641
  23. Wong T, Foote EF, Lefavour GS, Cody RP, Brown CJ, Sherman RA. Physician knowledge and practice patterns relating to diabetic nephropathy. J Am Pharm Assoc (Wash). 1999;39:785–790
  24. Lenz O, Fornoni A. Chronic kidney disease care delivered by US family medicine and internal medicine trainees: Results from an online survey. BMC Med. 2006;4:30
  25. Cooke CE, Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J Manag Care Pharm. 2006;12:649–655
  26. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46:1080–1087
  27. Cook S, Drum ML, Kirchhoff AC, et al. Providers' assessment of barriers to effective management of hypertension and hyperlipidemia in community health centers. J Health Care Poor Underserved. 2006;17:70–85
  28. Margolis KL, Rolnick SJ, Fortman KK, Maciosek MV, Hildebrant CL, Grimm RH. Self-reported hypertension treatment beliefs and practices of primary care physicians in a managed care organization. Am J Hypertens. 2005;18:566–571
  29. Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation. 2008;117:905–914
  30. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med. 2007;167:2431–2436
  31. Persson M, Carlberg B, Tavelin B, Lindholm LH. Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: Fair risk assessment but defensive treatment policy. J Hypertens. 2004;22:65–71
  32. Minutolo R, De Nicola L, Zamboli P, et al. Management of hypertension in patients with CKD: Differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46:18–25
  33. Huse DM, Roht LH, Alpert JS, Hartz SC. Physicians' knowledge, attitudes, and practice of pharmacologic treatment of hypertension. Ann Pharmacother. 2001;35:1173–1179

 Originally published online as doi: 10.1053/j.ajkd.2009.01.258 on April 10, 2009.

PII: S0272-6386(09)00428-4

doi: 10.1053/j.ajkd.2009.01.258

American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 238-247 , August 2009

Article Tools